Medullary thyroid carcinoma: Molecular signaling pathways and emerging therapies

Journal of Thyroid Research

Volumn 2011, Issue , 2011, Pages

  Gómez, Karen ^a   Varghese, Jeena ^b   Jiménez, Camilo ^b  

^a HOSPITAL SAN JUAN DE DIOS   (Costa Rica)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; CABOZANTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; LENVATINIB; PAZOPANIB; PLACEBO; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TIPIFARNIB; TRIACYLGLYCEROL LIPASE; TYROSINE KINASE RECEPTOR; VANDETANIB; VASCULOTROPIN;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPLASTIC THYROID CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PREVENTION; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HAIR DISEASE; HAIR HYPOPIGMENTATION; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OFF LABEL DRUG USE; ONCOGENE C MET; ONCOGENE RET; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN EXFOLIATION; SOLID TUMOR; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID SURGERY; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VASCULARIZATION; WEIGHT REDUCTION;

EID: 84859536073     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.4061/2011/815826     Document Type: Review

References (84)

1. R. A. De Lellis, R. Lloyd, P. U. Heitz, and C. Eng, WHO Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs, IARC Press, Lyon, France, 2004.
2. L. Davies and H. G. Welch, "Increasing incidence of thyroid cancer in the United States, 1973.2002", Journal of the American Medical Association, vol. 295, no. 18, pp. 2164.2167, 2006.
3. J. B. Hazard, W. A. Hawk, and G. Crile Jr., "Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity", Journal of Clinical Endocrinology & Metabolism, vol. 19, no. 1, pp. 152-161, 1959.
4. J. H. Sipple, "The association of pheochromocytoma with carcinoma of the thyroid gland", The American Journal of Medicine, vol. 31, no. 1, pp. 163.166, 1961.
5. E. D. Williams, C. L. Brown, and I. Doniach, "Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid", Journal of Clinical Pathology, vol. 19, no. 2, pp. 103.113, 1966.
6. E. D. Williams, "Histogenesis of medullary carcinoma of the thyroid", Journal of Clinical Pathology, vol. 19, no. 2, pp. 114-118, 1966.
7. K. Graze, I. J. Spiler, A. H. Tashjian Jr. et al., "Natural history of familial medullary thyroid carcinoma. Effect of a program for early diagnosis", New England Journal of Medicine, vol. 299, no. 18, pp. 980.985, 1978.
8. H. Donis-Keller, S. Dou, D. Chi et al., "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC", Human Molecular Genetics, vol. 2, no. 7, pp. 851.856, 1993.
9. L. M. Mulligan, J. B. J. Kwok, C. S. Healey et al., "Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A", Nature, vol. 363, no. 6428, pp. 458.460, 1993.
10. S. Dvorǎká, E. Václavíková, V. Sýkorová et al., "New multiple somaticmutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma", Thyroid, vol. 16, no. 3, pp. 311.316, 2006.
11. R. Elisei, B. Cosci, C. Romei et al., "Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study", Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 3, pp. 682.687, 2008.
12. C. Romei, B. Cosci, G. Renzini et al., "RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)", Clinical Endocrinology, vol. 74, no. 2, pp. 241.247, 2011.
13. E. Gardner, L. Papi, D. F. Easton et al., "Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2", Human Molecular Genetics, vol. 2, no. 3, pp. 241.246, 1993.
14. B. Pasini, R. M. W. Hofstra, L. Yin et al., "The physical map of the human RET proto-oncogene", Oncogene, vol. 11, no. 9, pp. 1737.1743, 1995.
15. M. Takahashi, Y. Buma, T. Iwamoto, Y. Inaguma, H. Ikeda, and H. Hiai, "Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains", Oncogene, vol. 3, no. 5, pp. 571.578, 1988.
16. T. Iwamoto, M. Taniguchi, N. Asai, K. Ohkusu, I. Nakashima, and M. Takahashi, "cDNA cloning of mouse ret protooncogene and its sequence similarity to the cadherin superfamily", Oncogene, vol. 8, no. 4, pp. 1087.1091, 1993.
17. J. Anders, S. Kjær, and C. F. Ibáñez, "Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site", Journal of Biological Chemistry, vol. 276, no. 38, pp. 35808.35817, 2001.
18. M. S. Airaksinen and M. Saarma, "The GDNF family: signalling, biological functions and therapeutic value", Nature Reviews Neuroscience, vol. 3, no. 5, pp. 383.394, 2002.
19. B. A. Tsui-Pierchala, J. Milbrandt, and E. M. Johnson Jr., "NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons", Neuron, vol. 33, no. 2, pp. 261.273, 2002.
20. J. W. B. De Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra, "RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors", Endocrine Reviews, vol. 27, no. 5, pp. 535.560, 2006.
21. M. Takahashi, "The GDNF/RET signaling pathway and human diseases", Cytokine and Growth Factor Reviews, vol. 12, no. 4, pp. 361.373, 2001.
22. M. Ichihara, Y. Murakumo, and M. Takahashi, "RET and neuroendocrine tumors", Cancer Letters, vol. 204, no. 2, pp. 197.211, 2004.
23. C. Eng, "Seminars in medicine of the Beth Israel Hospital, Boston: the RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease", New England Journal of Medicine, vol. 335, no. 13, pp. 943.951, 1996.
24. K. M. Zbuk and C. Eng, "Cancer phenomics: RET and PTEN as illustrative models", Nature Reviews Cancer, vol. 7, no. 1, pp. 35.45, 2007.
25. C. Jimënez, M. I.-N. Hu, and R. F. Gagel, "Management of medullary thyroid carcinoma", Endocrinology and Metabolism Clinics of North America, vol. 37, no. 2, pp. 481.496, 2008.
26. J. F. Moley and M. K. De Benedetti, "Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection", Annals of Surgery, vol. 229, no. 6, pp. 880.888, 1999.
27. D. J. Marsh, D. L. Learoyd, S. D. Andrew et al., "Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma", Clinical Endocrinology, vol. 44, no. 3, pp. 249.257, 1996.
28. H. J. Wolfe, K. E. Melvin, S. J. Cervi-Skinner et al., "Ccell hyperplasia preceding medullary thyroid carcinoma", New England Journal of Medicine, vol. 289, no. 9, pp. 437.441, 1973.
29. M. Drosten and B. M. Pützer, "Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy", Nature Clinical Practice Oncology, vol. 3, no. 10, pp. 564.574, 2006.
30. A. M. Hennige, R. Lammers, D. Arlt et al., "Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells, "Molecular and Cellular Endocrinology, vol. 167, no. 1-2, pp. 69-76, 2000.
31. H. Murakami, T. Iwashita, N. Asai et al., "Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by Ret with the MEN 2B mutation", Biochemical and Biophysical Research Communications, vol. 262, no. 1, pp. 68-75, 1999. (Pubitemid 29412625)
32. R. N. Jorissen, F. Walker, N. Pouliot, T. P. J. Garrett, C. W. Ward, and A. W. Burgess, "Epidermal growth factor receptor: mechanisms of activation and signalling", Experimental Cell Research, vol. 284, no. 1, pp. 31-53, 2003. (Pubitemid 36331965)
33. T. Holbro, G. Civenni, and N. E. Hynes, "The ErbB receptors and their role in cancer progression", Experimental Cell Research, vol. 284, no. 1, pp. 99-110, 2003. (Pubitemid 36331969)
34. G. Vlahovic and J. Crawford, "Activation of tyrosine kinases in cancer", Oncologist, vol. 8, no. 6, pp. 531-538, 2003. (Pubitemid 37467368)
35. C. L. Arteaga, "ErbB-targeted therapeutic approaches in human cancer", Experimental Cell Research, vol. 284, no. 1, pp. 122-130, 2003. (Pubitemid 36331971)
36. I. Vivanco and I. K. Mellinghoff, "Epidermal growth factor receptor inhibitors in oncology", Current Opinion in Oncology, vol. 22, no. 6, pp. 573-578, 2010.
37. P. Traxler, "Tyrosine kinases as targets in cancer therapy-successes and failures", Expert Opinion on Therapeutic Targets, vol. 7, no. 2, pp. 215-234, 2003. (Pubitemid 36512022)
38. M. Croyle, N. Akeno, J. A. Knauf et al., "RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR", Cancer Research, vol. 68, no. 11, pp. 4183-4191, 2008.
39. C. Rodríguez-Antona, J. Pallares, C. Montero-Conde et al., "Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis", Endocrine-Related Cancer, vol. 17, no. 1, pp. 7-16, 2010.
40. B. I. Terman, M. Dougher-Vermazen, M. E. Carrion et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor", Biochemical and Biophysical Research Communications, vol. 187, no. 3, pp. 1579-1586, 1992.
41. M. Shibuya and L. Claesson-Welsh, "Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis", Experimental Cell Research, vol. 312, no. 5, pp. 549-560, 2006. (Pubitemid 43290332)
42. R. S. Kerbel, "Tumor angiogenesis", New England Journal of Medicine, vol. 358, no. 19, pp. 2039-2049, 2008. (Pubitemid 351656458)
43. K. Alitalo and P. Carmeliet, "Molecular mechanisms of lymphangiogenesis in health and disease", Cancer Cell, vol. 1, no. 3, pp. 219-227, 2002. (Pubitemid 41039145)
44. C. Capp, S. M. Wajner, D. R. Siqueira, B. A. Brasil, L. Meurer, and A. L. Maia, "Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma", Thyroid, vol. 20, no. 8, pp. 863-871, 2010.
45. G. Bunone, P. Vigneri, L. Mariani et al., "Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features", American Journal of Pathology, vol. 155, no. 6, pp. 1967-1976, 1999.
46. D. P. Bottaro, J. S. Rubin, D. L. Faletto et al., "Identification of the hepatocyte growth factor receptor as the c-met protooncogene product", Science, vol. 251, no. 4995, pp. 802-804, 1991. (Pubitemid 21926175)
47. M. Sattler and R. Salgia, "The MET axis as a therapeutic target", Update on Cancer Therapeutics, vol. 3, no. 3, pp. 109-118, 2009.
48. S. Corso, C. Migliore, E. Ghiso, G. De Rosa, P. M. Comoglio, and S. Giordano, "Silencing the MET oncogene leads to regression of experimental tumors and metastases", Oncogene, vol. 27, no. 5, pp. 684-693, 2008. (Pubitemid 351158907)
49. M. Papotti, M. Olivero, M. Volante et al., "Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid", Endocrine Pathology, vol. 11, no. 1, pp. 19-30, 2000. (Pubitemid 30307941)
50. D. Vitagliano, V. De Falco, A. Tamburrino et al., "The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells", Endocrine-Related Cancer, vol. 18, no. 1, pp. 1-11, 2011.
51. A. Ocana, E. Amir, B. Seruga, and A. Pandiella, "Do we have to change the way targeted drugs are developed?" Journal of Clinical Oncology, vol. 28, no. 24, pp. e420-e421, 2010.
52. R. S. Herbst, J. V. Heymach, M. S. O'Reilly, A. Onn, and A. J. Ryan, "Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis", Expert Opinion on Investigational Drugs, vol. 16, no. 2, pp. 239-249, 2007. (Pubitemid 46206638)
53. P. P. Knowles, J. Murray-Rust, S. Kjær et al., "Structure and chemical inhibition of the RET tyrosine kinase domain", Journal of Biological Chemistry, vol. 281, no. 44, pp. 33577-33587, 2006. (Pubitemid 46036738)
54. F. Carlomagno, D. Vitagliano, T. Guida et al., "ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases", Cancer Research, vol. 62, no. 24, pp. 7284-7290, 2002. (Pubitemid 36025251)
55. F. Carlomagno, T. Guida, S. Anaganti et al., "Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors", Oncogene, vol. 23, no. 36, pp. 6056-6063, 2004. (Pubitemid 39178858)
56. V. Johanson, H. Ahlman, P. Bernhardt et al., "A transplantable humanmedullary thyroid carcinoma as amodel for RET tyrosine kinase-driven tumorigenesis", Endocrine-Related Cancer, vol. 14, no. 2, pp. 433-444, 2007. (Pubitemid 47242641)
57. S. N. Holden, S. G. Eckhardt, R. Basser et al., "Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors", Annals of Oncology, vol. 16, no. 8, pp. 1391-1397, 2005. (Pubitemid 41158486)
58. S. A. Wells Jr., J. E. Gosnell, R. F. Gagel et al., "Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer", Journal of Clinical Oncology, vol. 28, no. 5, pp. 767-772, 2010.
59. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., "New guidelines to evaluate the response to treatment in solid tumors", Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205-216, 2000. (Pubitemid 30099779)
60. B. G. Robinson, L. Paz-Ares, A. Krebs, J. Vasselli, and R. Haddad, "Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer", Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2664-2671, 2010.
61. N. Akeno-Stuart, M. Croyle, J. A. Knauf et al., "The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells", Cancer Research, vol. 67, no. 14, pp. 6956-6964, 2007. (Pubitemid 47105543)
62. L. Ludwig, H. Kessler, M. Wagner et al., "Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RETinduced transformation", Cancer Research, vol. 61, no. 11, pp. 4526-4535, 2001. (Pubitemid 32685784)
63. C. S. Mitsiades, D. McMillin, V. Kotoula et al., "Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro", Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 10, pp. 4013-4021, 2006. (Pubitemid 44536879)
64. F. Carlomagno, S. Anaganti, T. Guida et al., "BAY 43-9006 inhibition of oncogenic RET mutants", Journal of the National Cancer Institute, vol. 98, no. 5, pp. 326-334, 2006. (Pubitemid 43338212)
65. A. Degen, M. Alter, F. Schenck et al., "The handfootsyndrome associated with medical tumor therapy-classification and management", Journal of the German Society of Dermatology, vol. 8, no. 9, pp. 652-662, 2010.
66. D. Strumberg, J. W. Clark, A. Awada et al., "Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors", Oncologist, vol. 12, no. 4, pp. 426-437, 2007. (Pubitemid 46698720)
67. F. Kober, M. Hermann, A. Handler, and G. Krotla, "Effect of sorafenib in symptomatic metastatic medullary thyroid cancer", Journal of Clinical Oncology, vol. 25, abstract 14065, 2007.
68. E. T. Lam, M. D. Ringel, R. T. Kloos et al., "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer", Journal of Clinical Oncology, vol. 28, no. 14, pp. 2323-2330, 2010.
69. S. I. Sherman, "NCCN Practice guidelines for thyroid cancer", Version 1.2011. 2011.
70. D. S. Hong, S. M. Sebti, R. A. Newman et al., "Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies", Clinical Cancer Research, vol. 15, no. 22, pp. 7061-7068, 2009.
71. D. Hong, L. Ye, R. Gagel et al., "Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib", Molecular Cancer Therapeutics, vol. 7, no. 5, pp. 1001-1006, 2008.
72. A. M. Tsimberidou, C. Chandhasin, and R. Kurzrock, " Farnesyltransferase inhibitors: where are we now?" Expert Opinion on Investigational Drugs, vol. 19, no. 12, pp. 1569-1580, 2010.
73. C. Lanzi, G. Cassinelli, V. Nicolini, and F. Zunino, "Targeting RET for thyroid cancer therapy", Biochemical Pharmacology, vol. 77, no. 3, pp. 297-309, 2009.
74. C. Romei, S. Mariotti, L. Fugazzola et al., "Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes", European Journal of Endocrinology, vol. 163, no. 2, pp. 301-308, 2010.
75. D. B. Mendel, A. D. Laird, X. Xin et al., "In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship", Clinical Cancer Research, vol. 9, no. 1, pp. 327-337, 2003. (Pubitemid 36109749)
76. E. E. Cohen, B. M. Needles, K. J. Cullen et al., "Phase 2 study of sunitinib in refractory thyroid cancer", Journal of Clinical Oncology, vol. 26, abstract 6025, 2008.
77. J. A. De Souza, N. Busaidy, A. Zimrin et al., "Phase II trial of sunitinib in medullary thyroid cancer (MTC)", Journal of Clinical Oncology, vol. 28, abstract 5504, 2010.
78. L. L. Carr, D. A. Mankoff, B. H. Goulart et al., "Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation", Clinical Cancer Research, vol. 16, no. 21, pp. 5260-5268, 2010.
79. J. P. Eder, G. F. Van de Woude, S. A. Boerner, and P. M. Lorusso, "Novel therapeutic inhibitors of the c-Met signaling pathway in cancer", Clinical Cancer Research, vol. 15, no. 7, pp. 2207-2214, 2009.
80. S. I. Sherman, "Targeted therapy of thyroid cancer", Biochemical Pharmacology, vol. 80, no. 5, pp. 592-601, 2010.
81. J. Matsui, Y. Yamamoto, Y. Funahashi et al., "E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition", International Journal of Cancer, vol. 122, no. 3, pp. 664-671, 2008. (Pubitemid 350308963)
82. R. J. Keizer, A. Gupta, M. R. MacGillavry et al., "A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080", Journal of Pharmacokinetics and Pharmacodynamics, vol. 37, no. 4, pp. 347-363, 2010.
83. G. Sonpavde, T. E. Hutson, and C. N. Sternberg, "Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma", Expert Opinion on Investigational Drugs, vol. 17, no. 2, pp. 253-261, 2008. (Pubitemid 351578205)
84. K. C. Bible, V. J. Suman, J. R. Molina et al., "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study", The Lancet Oncology, vol. 11, no. 10, pp. 962-972, 2010.